568 related articles for article (PubMed ID: 30392213)
1. [Analysis of the influencing factors of recombinant human growth hormone effect in the children with Turner syndrome].
Li J; Wu W; Liang Y; Luo XP
Zhonghua Er Ke Za Zhi; 2018 Nov; 56(11):866-870. PubMed ID: 30392213
[No Abstract] [Full Text] [Related]
2. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
3. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
4. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
Binder G; Trebar B; Baur F; Schweizer R; Ranke MB
Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
[TBL] [Abstract][Full Text] [Related]
5. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
6. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
7. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome.
Ko JM; Kim JM; Cheon CK; Kim DH; Lee DY; Cheong WY; Kim EY; Park MJ; Yoo HW
Clin Endocrinol (Oxf); 2010 Feb; 72(2):196-202. PubMed ID: 19681916
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
[TBL] [Abstract][Full Text] [Related]
9. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
[TBL] [Abstract][Full Text] [Related]
10. Relationship between initial treatment effect of recombinant human growth hormone and exon 3 polymorphism of growth hormone receptor in Chinese children with growth hormone deficiency.
Zheng Z; Cao L; Pei Z; Zhi D; Zhao Z; Xi L; Cheng R; Luo F
Int J Clin Exp Med; 2015; 8(5):7965-70. PubMed ID: 26221355
[TBL] [Abstract][Full Text] [Related]
11. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
[TBL] [Abstract][Full Text] [Related]
12. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
Dörr HG; Bettendorf M; Hauffa BP; Mehls O; Rohrer T; Stahnke N; Pfäffle R; Ranke MB;
Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
[TBL] [Abstract][Full Text] [Related]
13. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
14. Correlation between exon 3 polymorphism of growth hormone receptor gene and the responses to rhGH therapy.
Wei Y; Zheng R; Zhou Y; Wang J; Bao P
Int J Clin Exp Pathol; 2015; 8(6):7371-7. PubMed ID: 26261638
[TBL] [Abstract][Full Text] [Related]
15. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature.
Toyoshima MT; Castroneves LA; Costalonga EF; Mendonca BB; Arnhold IJ; Jorge AA
Clin Endocrinol (Oxf); 2007 Oct; 67(4):500-4. PubMed ID: 17555512
[TBL] [Abstract][Full Text] [Related]
16. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
[TBL] [Abstract][Full Text] [Related]
17. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
19. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.
Carrascosa A; Esteban C; Espadero R; Fernández-Cancio M; Andaluz P; Clemente M; Audí L; Wollmann H; Fryklund L; Parodi L;
J Clin Endocrinol Metab; 2006 Sep; 91(9):3281-6. PubMed ID: 16804042
[TBL] [Abstract][Full Text] [Related]
20. The distribution of exon 3-deleted/full-length growth hormone receptor polymorphism in the Turkish population.
Baş F; Keleşoğlu F; Timirci Ö; Kabataş Eryılmaz S; Bozkurt N; Küçükemre Aydın B; Bundak R; Isbir T; Darendeliler F
J Clin Res Pediatr Endocrinol; 2011; 3(3):126-31. PubMed ID: 21911325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
